ArticleBlood2008

Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.

Emanuela M Ghia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.